Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 1999 March;41(1) > Panminerva Medica 1999 March;41(1):68-71





Rivista di Medicina Interna

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6




Panminerva Medica 1999 March;41(1):68-71

lingua: Inglese

Serum and sal­i­vary ­antiendo­my­sium anti­bod­ies in the screen­ing of ­coeliac dis­ease

Di Leo M., Weisz G.*, Ansaldi Balocco N.

From the Department of Pediatrics and Adolescence Sciences Chair of Pediatrics, Gastroenterology Section University of Turin and the *Analysis Laboratory, Martini Nuovo Hospital, Turin, Italy


Background. Antiendomysium anti­bod­ies (EMA) detec­tion in ser­um is the ­best screen­ing ­test for ­coeliac dis­ease (CD): in sali­va it has not yet ­been ­assayed. Aims of ­this ­study are: to ver­i­fy the pres­ence of EMA in sali­va col­lect­ed ­with a not inva­sive tech­nique; to eval­u­ate the valid­ity of ser­um and sal­i­vary EMA in CD screen­ing.
Methods. We inves­ti­gat­ed 130 sub­jects divid­ed into 3 ­groups: “A”: 45 untreat­ed CD ­patients (­mean age 6.11); “B”:18 CD ­patients treat­ed ­with a glu­ten ­free ­diet (­mean age 13.2); “C”: 67 con­trols ( ­mean age 8.9). We per­formed the EMA ­test ­using the indi­rect immu­no­flu­o­res­cence tech­nique, in ser­um and in sali­va con­cen­trat­ed sam­ples.
Results. Our ­results ­show: sen­si­tiv­ity EMA ser­um 100%; spec­i­fic­ity EMA ser­um 96.5%; sen­si­tiv­ity EMA sali­va 46.5%; spec­i­fic­ity EMA sali­va 100%; pos. ­pred. val­ue EMA ser­um 93.5%; neg. ­pred. val­ue ser­um 100%; pos. ­pred. val­ue EMA sali­va 100%; neg. ­pred. val­ue sali­va 78.7%.
Conclusions. Conclusion indi­cates a ­high spec­i­fic­ity of sal­i­vary EMA and a ­high sen­si­tiv­ity of ser­um EMA, anyway biop­sy is ­still rec­om­mend­ed for diag­no­sis of CD.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail